Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium
Information source: Seoul National University Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Observation of Neuromuscular Block
Intervention: Injection of neostigmine (Drug)
Phase: N/A
Status: Completed
Sponsored by: Seoul National University Hospital Official(s) and/or principal investigator(s): Ah Young Oh, Principal Investigator, Affiliation: Professor
Summary
This study aims to find appropriate dose of neostigmine which is possible to reverse
rocuronium or cisatracurium till train of four (TOF) 0. 9 within 10 minutes.
Clinical Details
Official title: Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: time to reverse from light muscle relaxation
Secondary outcome: time to reverse from TOF ratio 0.5 to 0.9
Eligibility
Minimum age: 19 Years.
Maximum age: 69 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- American Society of Anesthesiologist Physical status classification 1 or 2 elective
surgery under general anesthesia
Exclusion Criteria:
- BMI >25 or < 20 kg/m2
- Patients taking intercurrent medication
- Glutamic Oxalacetate Transaminase or Glutamic Pyruvate Transaminase > 40 IU/L, Cr >
1. 4 mg/dl
Locations and Contacts
Eunsu Choi, Seongnam-si, Gyeonggi-do 463-707, Korea, Republic of
Additional Information
Starting date: June 2013
Last updated: June 12, 2014
|